Brokerages Set Inspire Medical Systems, Inc. (NYSE:INSP) Price Target at $68.00

Inspire Medical Systems, Inc. (NYSE:INSP) has received a consensus recommendation of “Hold” from the twenty analysts that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, thirteen have given a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $68.00.

A number of equities analysts recently weighed in on INSP shares. Robert W. Baird increased their price objective on shares of Inspire Medical Systems from $54.00 to $59.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Wells Fargo & Company cut their target price on Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 5th. Zacks Research upgraded Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Royal Bank Of Canada restated a “sector perform” rating and set a $60.00 price target on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Finally, Bank of America lowered Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price target for the company. in a research report on Friday, May 22nd.

Inspire Medical Systems Trading Down 1.6%

Shares of INSP opened at $57.26 on Wednesday. The company’s 50-day moving average price is $49.38 and its 200 day moving average price is $53.47. Inspire Medical Systems has a 12-month low of $38.91 and a 12-month high of $147.03. The firm has a market cap of $1.66 billion, a P/E ratio of 12.39, a price-to-earnings-growth ratio of 4.42 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.38. The company had revenue of $200.58 million during the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. Inspire Medical Systems’s revenue was down 7.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Equities research analysts forecast that Inspire Medical Systems will post 1.24 earnings per share for the current year.

Insider Buying and Selling

In other Inspire Medical Systems news, insider Jason P. Kelly sold 963 shares of Inspire Medical Systems stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the transaction, the insider directly owned 18,985 shares of the company’s stock, valued at $1,130,556.75. The trade was a 4.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 2.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Inspire Medical Systems during the 2nd quarter worth approximately $211,341,000. Wellington Management Group LLP purchased a new position in Inspire Medical Systems in the 4th quarter valued at approximately $203,929,000. Wasatch Advisors LP grew its stake in shares of Inspire Medical Systems by 7.2% in the second quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock worth $212,095,000 after acquiring an additional 110,288 shares in the last quarter. Morgan Stanley grew its stake in shares of Inspire Medical Systems by 179.5% in the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock worth $116,188,000 after acquiring an additional 809,121 shares in the last quarter. Finally, Deerfield Management Company L.P. increased its position in shares of Inspire Medical Systems by 648.4% during the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after acquiring an additional 907,694 shares during the period. Institutional investors and hedge funds own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.